Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PASTEUR MERIEUX’s ActHIB TO BE MARKETED BY SMITHKLINE BEECHAM

Executive Summary

PASTEUR MERIEUX's ActHIB TO BE MARKETED BY SMITHKLINE BEECHAM following the March 31 approval of the Haemophilus b conjugate vaccine. ActHIB is the fourth vaccine against Haemophilus influenzae type b approved in the U.S., following Connaught's ProHIBIT, Merck's PedvaxHIB and Lederle's HibTITER. ActHIB is indicated for immunization of infants and children from two months to five years of age. Under a June 1992 agreement, Pasteur Merieux will supply SmithKline Beecham with ActHIB until the U.S. firm is able to manufacture the vaccine itself. The Clinton Administration's consolidated vaccine purchasing proposal announced April 1 may delay that process. In response to the administration announcement, SmithKline Beecham President of North American Operations J.P. Garnier said that the company is "freezing" the process of choosing a site for a new $10 mil. pediatric vaccine facility until the details of the program are clear (see related story, p. 14). The approval of ActHIB came one day after FDA's clearance of Lederle's Tetramune, a combination Haemophilus b conjugate and diphtheria-tetanus toxoids-pertussis vaccine (see preceding T&G). Both of the vaccines were recommended for approval by FDA's Vaccines and Related Biologics Advisory Committee at its Oct. 28 meeting ("The Pink Sheet" Nov. 2, 1992, p. 12). At that meeting, the advisory committee rejected a Pasteur Merieux proposal that ActHIB labeling direct physicians to reconstitute the Haemophilus b vaccine with Connaught DTP vaccine. ActHIB labeling states that the vaccine has been routinely administered concomitantly with DTP and other vaccines, but does not advise the physician to reconstitute the vaccines together. Labeling notes that "interference with the antibody response to the pertussis component has been suggested with a DTP vaccine unlicensed in the U.S." The reference is to a study reported in the Journal of the American Medical Association that found lower pertussis agglutinin titers in Chilean children immunized with ActHIB and Pasteur's DTP vaccine compared to DTP alone.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

ID1132028

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel